Related Experiment Video

Updated: Jul 4, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment

Lin Liu1, Min Zhang, Ping Zou

  • 1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Oncology
|June 13, 2008
PubMed
Abstract

Insights

Polo-like kinase 1 (PLK1) is overexpressed in 63.6% of non-Hodgkin's lymphoma (NHL) cases, correlating with poorer outcomes. Targeting PLK1 shows promise as a novel therapeutic strategy for NHL treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Non-Hodgkin's lymphoma (NHL) is a heterogeneous group of lymphoid malignancies.
  • Identifying novel therapeutic targets is crucial for improving NHL patient outcomes.

Purpose of the Study:

  • To detect polo-like kinase 1 (PLK1) expression in NHL.
  • To evaluate PLK1 as a potential therapeutic target for NHL.

Main Methods:

  • Immunohistochemistry was used to detect PLK1 expression in NHL tissues.
  • RNA interference was employed to deplete PLK1 in lymphoma cell lines.
  • Cell proliferation, cell cycle, and apoptosis were assessed using MTT assays and flow cytometry.

Main Results:

  • PLK1 was expressed in 63.6% of NHL patients (56/88).
  • PLK1 expression correlated with clinical parameters and was an independent prognostic factor for NHL.
  • PLK1 depletion suppressed lymphoma cell growth, induced cell cycle arrest, and promoted apoptosis.

Conclusions:

  • PLK1 overexpression is an adverse prognostic indicator in NHL.
  • PLK1 represents a promising novel therapeutic target for NHL treatment.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...